The iTrend research team of Paul Stewart; Jill Stewart; Maarten Taal; Nicholas Selby; Mohamed Tarek Eldehni and Venkata R Latha Gullapudi hold the US patent which is valid until 2048.

The team is embarking on the next phase of study taking the device and software towards commercialisation in the iTrend NXG project which starts on 1st December 2024, and is based at Derby University, University of Nottingham and the Centre for Kidney Research and Innovation based at Royal Derby Hospital.